Previous 10 | Next 10 |
This article was first released to CEF/ETF Income Laboratory subscribers two weeks ago. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund ((CEF)) sectors in the last week, as well as to highlight recently c...
Tekla Life Sciences Investors (the “Fund”) announced today that its Board of Trustees authorized a renewal of its share repurchase program. The current share repurchase program allows the Fund to purchase in the open market up to 12% of its outstanding common shares for a one-y...
This article was first released to subscribers 2 weeks ago. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund ((CEF)) sectors in the last week, as well as to highlight recently concluded or upcoming corporate...
This article was first released to subscribers 2 weeks ago. The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corpora...
We're only two-thirds of the way through February 2019, but the pace at which distressed U.S. firms are announcing dividend cuts has picked up considerably. Unlike what we saw in January 2019, however, the near-real time sources that we track for dividend cut announcements suggests that di...
On February 15, 2019, Tekla Life Sciences Investors declared a stock distribution of $0.33 per share. The record date for the stock distribution is February 28, 2019 and the payable date is March 29, 2019. The Fund will trade ex-distribution on February 27, 2019. This stock distribution ...
By Andy Acker, CFA & Daniel Lyons, Ph.D., CFA & John Scotti, D.Phil. The biotech industry is experiencing a renaissance, with the U.S. approving a record number of novel therapies in 2018. But not all drugs are created equal, say members of the Janus Henderson Global Life Sciences...
For more conservative investors, my top income pick for the coming year is Tekla Life Sciences Investors ( HQL ), a closed-end fund, explains Nate Pile , editor of Nate's Notes and a specialist in healthcare and biotechnology stocks. This closed-end fund invests in a variety of pu...
2018 seems to be ending on a bad note in the markets. December is setting the wrong kind of records, and Q4 has been a bumpy one in general. This is what happens in the stock market sometimes, but it's been easy to forget over the decade-long bull market. We're using the end of the year as a...
The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information...
News, Short Squeeze, Breakout and More Instantly...
TeklaLife Sciences Investors Company Name:
HQL Stock Symbol:
NYSE Market:
TeklaLife Sciences Investors Website:
2024-08-01 06:54:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-25 05:00:37 ET Few people pay much attention to the management team of a closed-end fund (CEF). But it’s becoming a much more critical factor driving CEF upside (and downside!), as well as these funds’ 8%+ dividend payouts. I was reminded of this recently by a ...
PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / abrdn Life Sciences Investors ("HQL") announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024. As of the record date, April 1, 2024, HQL had outstanding 27,350,517 shares of common stock. 87.84% o...